Gland Pharma posts record revenue, nearly doubles profit in Q4 FY26

The 38% adjusted EBITDA margin of base business has been supported by robust growth in the CDMO segment

Solara's strong Q4 lifts FY26 finish but ibuprofen drag forces strategic review

The Ibuprofen business posted a negative EBITDA of Rs. 179 million in Q4 despite revenue rising 61% year-on-year to Rs. 849 million

Medanta delivers record FY26 performance as revenue surges & profit jumps with expansion

Medanta expanded its bed capacity by 20% during the year

OneSource records Rs. 4,282 million revenue in Q4 FY26

Backed by Semaglutide launches, the company reported 47% quarter-on-quarter revenue growth in Q4 FY26, with EBITDA expanding more than fivefold

Senores Pharma reports 62% rise in FY26 total income to Rs. 664 crore

The company reported a 108% rise in profit after tax, driven by strong growth in regulated markets, branded generics, and U.S. expansion initiatives

Cipla achieves highest-ever annual revenue of Rs. 28,163 crore in FY26

The company witnesses strong growth across its India, Africa, and emerging markets businesses, while securing regulatory approval for the first AB-rated gVentolin in the U.S. market

Akums posts strong FY26 performance as EBITDA surges 61.6% in Q4

Neuland Laboratories posts blockbuster FY26 performance

CORONA Remedies posts robust FY26 with 17.3% revenue growth, 33.4% PAT surge

The company highlighted a series of strategic moves during the year, including the acquisition of WOKADINE, marking its entry into the Rs. 648 Cr Povidone Iodine market

JB Chemicals reports muted Q4 FY26 as integration resets business

The CDMO segment saw a 22% decline in Q4 due to a strong base in the prior year